The ranking of the world's top 100 pharmaceutical companies is open! China dominates 208 Hengrui, Shi medicine and other leading charges.

In 2012, Torreya, the global investment bank, began researching 30,000 pharmaceutical companies worldwide.
2020, the agency released the Global 1000 Pharmaceutical Companies Report, which ranks 1,000 drug companies by market capitalisation, with annual revenues of more than $1.2 trillion.
estimates that the global pharmaceutical industry is now worth $6.65 trillion, up 24.3 percent year-on-year.
, $5.65 trillion is related to public companies.
if the pharmaceutical industry were to be seen as a country, it would rank 15th in the world, surpassing the GDP of Mexico, Indonesia, Sweden or Poland.
is worth noting that the pharmaceutical industry has become the third most valuable industry outside of finance and e-commerce, and the Internet, while in China, the biopharmaceutical industry has become the second most valuable industry outside of banks.
the past five years, the pharmaceutical industry has gradually shifted from developed western countries, mainly the United States, Switzerland, Germany and France, to Asia, where China, Japan and South Korea are located.
, China is particularly prominent, with the pharmaceutical industry increasing output by more than $350 billion, or about 100 per cent.
's share of global total value also jumped from 6.5 percent in 2015 to 14.4 percent in September 2020, surpassing Switzerland as the second-largest country after the U.S., which fell 3.5 percent over the same period, Switzerland fell 3.2 percent and Japan rose 2.3 percent.
, drugs are moving faster and faster from small molecules to biologics.
between 2003 and 2015, the proportion of biologics increased by only 5.3% in 12 years, while in 2015-2020, biologics - an increase of $1 trillion - increased by $1 trillion, and the market share increased by 13.8% to 33.6%.
, the market share of small-molecule drugs fell 15.5 per cent to 59.9 per cent over the same period.
vaccines, nucleic acids and peptides are rising rapidly, especially this year's explosive growth of vaccines, Kantai Bio, Watson Bio, Hualan Bio three local vaccine companies this year's market value soared, from 100 outside, or even 200 outside the break-out into the top 100.
note that Big Pharma is not as important as it was five years ago, when innovation blossomed every day.
in 2003, the top 18 pharmaceutical companies accounted for 77 per cent of total value and dominated the industry;
Domestic side, to Hengrui Pharmaceuticals, Stone Pharmaceutical Group, Howson Pharmaceuticals, led by the three major local large-scale pharmaceutical breakthrough, and baiji Shenzhou, Xinda Biology, Junshi Bio's local Biotech is more violent speed to break through, this year they rushed from 200 outside the 100, from 100 outside the challenge TOP50.
, however, generic drugs face an awkward situation.
market value of the generic drug industry has fallen over the past five years as price competition has intensified.
2015, the top 10 generic drug companies have fallen from 6.4 percent of global pharmaceutical value to less than 4 percent today.
the same is true at home, with Big Pharma, led by Yangzijiang and Qilu Pharmaceuticals, lying hard to withstand the downturn.
Hengrui, Shi medicine, Howson breakout, Yangzijiang status decline compared to 2019, TOP6's Big Pharma players have not changed, but the position is basically all disrupted.
first time this year, the cancer leader Roche took over from Pfizer as the dominant, to a certain extent, the official announced the cancer immunity in the field of treatment leading position.
the estimated value, "Cosmic Factory" Pfizer has dropped to No. 3, and Novarda, which was originally No. 3, has been squeezed out to No. 6.
as well as AstraZenech, Baxger BMS and No. 10, replacing Lilly, GlaxoSmithKline GSK and Sanofi.
,000-year-old Anjin rose from 10th last year to 7th this year.
is also noteworthy that the top10 MNC-led field has become a pattern of grading between biologics and small molecules.
domestic side, Hengrui Pharmaceuticals overred regenerative yuan, Germany Merck, Yan Jian and other pharmaceutical companies, from last year's 30th year to this year's 21st place.
is also worth noting that in the field of oncology, Hengrui Pharmaceuticals ranked higher, ranked 8th.
, Hengrui's market capitalisation moved from 400 billion yuan to 500 billion yuan, more than 250 times higher than in 2003.
, the agency said:
Henrui Pharmaceuticals brought oncology drugs to China when needed, without acquisitions, purely through in-house innovation and strong marketing throughout China."
" is firmly similar to the original introduction of tumors, under the outbreak sun fluttering and Hengrui's investment in research and development is also very firm.
the first half of this year, research and development investment maintained a 26% growth, in addition, Sun Yuyang retired and then started the first stop, is a joint venture with Hengrui Pharmaceuticals to set up a new company, Rydy, dedicated to the development of antiviral drugs.
Hengrui in the first half of the year to obtain innovative pharmaceutical preparation production batch 3, generic pharmaceutical preparation production batch 1, to obtain innovative drug clinical approval 37, to obtain 3 varieties of consistent evaluation batch, to complete the consistency evaluation of 2 products.
has been listed products, Hengrui also its innovative drug PD-1 external paid license to South Korea CG Company.
commercialization capabilities beyond its research and development capabilities, according to IQVIA data, its PD-1 products in the first half of this year sales of nearly 2 billion yuan, has exceeded K medicine.
Group is no less than that.
30th place among the top 1,000 drug companies with $5.3 billion in annual revenue and $35 billion in market capitalization, up 38 places from 68 in 2019.
addition to the overall ranking, Stone Pharmaceutical Group ranks 2nd in the world in the field of central neuropharmaceuticals by virtue of Erbip, and 16th in the field with GV-971 in Shanghai Green Valley Pharmaceuticals.
year to July, Ernbip's sales at sample hospitals nationwide were RMB2,947 million, up 16.2% year-on-year.
agency had predicted that the drug's 2025 sales will reach 10 billion yuan.
in the field of oncology, Howson Pharmaceuticals is ranked 12th after Hengrui Pharmaceuticals.
ranks 37th overall with a market capitalisation of $26 billion and revenue of $1.1 billion.
, Howson Pharmaceuticals launched the first domestic third-generation self-developed EGFR-TKI inhibitor Amethini.
, a strategic partnership was entered into with EQRx and a licensing agreement was entered into to license Amethini's overseas research, development, production and commercial rights to EQRx.
first half of this year, HOWSON Pharmaceuticals filed and obtained 10 new clinical approvals, applied for 10 applications for market, approved 6 new drugs (including 1 innovative drug, 2 first generic drugs), all generic drugs are evaluated consistently.
is currently in research projects more than 100, of which entered the clinical phase II and later stage of 5 innovative drugs, human biological equidition test (BE) (including declared production) 22.
is an opportunity to innovate large pharmaceuticals.
2011, when the agency counted the top 1000 drug companies, only One pharmaceutical company in TOP35 was leading the way.
time, the location of Yangzijiang is now the stone medicine, 30th place, more than Ale brother, Chugai, Vertex and other pharmaceutical companies.
2020, Yangzijiang will be ranked 27th, although up three places, but top 35 people may pay more attention to Hengrui, Shi medicine and Howson three Big Pharma.
, who were trampled under the feet of Yangzijiang a decade ago, have been left far behind.
are ranked 11th and 13th in market capitalisation this year.
, Baiji, Xinda, Junshi impact China will be able to birth a world-class innovative pharmaceutical enterprises? Don't worry, the seeded player has been born.
among the top 100 Chinese pharmaceutical companies on the list, Baiji Shenzhou, Xinda and Junshi are the brightest new stars.
has soared from 110 in 2019 to 52.
90 from 177 to 90, while The Real Creatures are brighter, rising from 265 in 2019 to 94 this year.
, unlike Hengrui, Shi Medicine and Changchun Gaoxin, these innovative pharmaceutical companies from scratch, their innovative genes are engraved in the bone, since its inception has determined to do innovative drugs.
as China's only innovative pharmaceutical research and development company with a market capitalization of hundreds of billions of dollars, after ten years of training, Baiji Shenzhou is starting a new wave of innovation.
2019, Zebutini, Baiji Shenzhou, was officially approved by the FDA of the United States, becoming the first local research and development of anti-cancer drugs listed in the United States, the realization of China's original research and development of new drugs out to sea "zero breakthrough."
in April this year, it was approved by the National Drug Administration (NMPA).
2020, Baiji Shenzhou, with zebtinib and Tyreli pearl single anti-urethra cancer adaptation certificate expansion, accounted for 2 pit positions, has been level with Heng Rui.
, which went on sale in March, generated 350 million yuan in sales in less than four months and is expected to contribute more than 1 billion yuan this year.
addition, Baiji Shenzhou this year introduced nine new drug authorizations, more than the whole of 2019.
is currently around PD-1, BTK and other products to expand new adaptation certificates, including lung cancer, liver cancer and other important areas.
next step, Baiji Shenzhou plans to use its advantages in TIGIT drugs to start the next decade.
In the capital market, Baiji Shenzhou is also sought after incense, at the beginning of this year, Baiji Shenzhou was the United States Amjin company worth about 2.8 billion U.S. dollars investment, July 13 the company announced the completion of a $2.08 billion in incremental issuance, breaking the biotechnology sector's largest equity financing record.
established in 2011, holding the second domestic approved domestic PD-1 Xindili single anti-Dabershu.
the product, Xinhua Bio's first commercial product, was brought to market in March 2019 and achieved sales of more than $1 billion in less than ten months.
first half sales of the goods, which will be included in the price reduction of health insurance in 2020, still reached 921 million yuan, close to last year's full-year figure, a growth rate of 177 percent, and is expected to sprint by 2 billion yuan this year.
not only Xindili monoanti, Xinda Bio has a number of products in research has entered the stage of accelerated commercialization.
, for example, the second monoclonal antibody drug to be approved by the NMPA, beva bead monoantigen injection, was officially approved by NMPA in June this year.
in early September, its third product Adamo single anti-injection Su Lixin was officially approved for the market.
this year, Xinda Bio has successfully established 23 research and development pipelines, with a total of more than 50 products in clinical trials.
addition, Xinda is well prepared for the commercialization of future products.
, Xinhua and Lilly expanded their global strategic partnership on the immuno-oncology drug PD-1 monoclonal antibody Dabershu.
and its Dabershu sales and marketing team has expanded from 700 at the end of last year to 1,100, and its coverage has expanded from 2,000 hospitals and 500 DTP pharmacies at the end of last year to about 3,500 hospitals and 900 DTP pharmacies in more than 300 cities.
in the list, almost catch up with Xinda's real biological strength can not be underestimated.
Xinda's first drug halo in China, the development momentum is strong.
the first half of this year, Junshi Bio achieved operating income of 575 million yuan, an increase of 85.88 percent year-on-year, and 15 key registered clinical trials have been conducted for the core product, Ripley Mono-Resistance (commodity name: Toyi).
recently, its PD-1 monoantigen Terripri monoantigen has been recognized by the FDA as a "breakthrough therapy" for nasopharyngeal cancer.
This is China's domestic market and in the study of PD-1 mono-resistance, the first FDA breakthrough therapy identified products, achieved a breakthrough in domestic PD-1 zero, and previously, Ripley monoantigen also in the field of mucosal melanoma, nasopharyngeal cancer, soft tissue sarcoma has been awarded three FDA "orphan drug" qualification.
it is understood that a new drug in the "breakthrough therapy" after the identification, generally in the phase II clinical stage to obtain preliminary clinical evidence, you can submit a listing application, listing applications can be submitted 6 to 10 months after approval.
means that the pace of clinical research and approved listings in the U.S. will be greatly accelerated.
the report shows that Junshi Bio has 21 products under study, including 19 innovative drugs, 2 bio-analogs, covering malignant tumors, autoimmune system diseases, chronic metabolic diseases, neurological diseases and infectious diseases in the five therapeutic areas.
addition, in order to enrich the company's research and development pipeline in the field of cancer treatment, in cooperation with micro-organisms, access to its four drugs worldwide exclusive production rights, commissioned production rights and sales rights.
, the three innovative Chinese pharmaceutical companies that were founded almost simultaneously, are now shining on the world stage after a decade of development, and that is just the beginning.
, as Wang Li, senior vice president of Baiji Shenzhou, said, "China has really reached the golden decade of pharmaceuticals, and after the accumulation of the previous decade, now is the time to make a force."
" Zhifei, Kantai, Watson surged in the first half of this year, under the influence of the epidemic, with Zhifei Biological, Kantai Biological, Hualan Biology, Watson Bio as the representative of the vaccine industry chain companies developed by leaps and downs.
the short term, the vaccine industry chain companies are expected to directly benefit from the progress of research and development and vaccination of the new crown vaccine, and in the medium to long term, the new crown outbreak has pushed the emphasis on vaccine research and development and industrialization to unprecedented heights.
the future, policies and rules that are good for the vaccine industry, such as vaccine reserve systems, vaccine technology upgrades, and policies to encourage vaccination support, may be accelerated to further improve the development of industry companies.
with $1.7 billion in annual revenue and 3.